汉黄芩素通过Hippo-Yes相关蛋白/含PDZ结合基序的转录共激活因子信号通路调控肝纤维化

邹晓婷 邓陈松 胡际涛 向海鸿 袁剑峰 严红梅

解剖学报 ›› 2026, Vol. 57 ›› Issue (2) : 185-193.

PDF(14053 KB)
欢迎访问《解剖学报》官方网站!今天是 English
PDF(14053 KB)
解剖学报 ›› 2026, Vol. 57 ›› Issue (2) : 185-193. DOI: 10.16098/j.issn.0529-1356.2026.02.006
细胞和分子生物学

汉黄芩素通过Hippo-Yes相关蛋白/含PDZ结合基序的转录共激活因子信号通路调控肝纤维化

  • 邹晓婷1邓陈松2*胡际涛1向海鸿1袁剑峰1严红梅3

作者信息 +

Effect of wogonin on liver fibrosis by regulating the Hippo-Yes-associated protein/transcriptional coactivator with PDZ-binding motif signaling pathway

  • ZOU Xiao-ting1, DENG Chen-song2*, HU Ji-tao1, XIANG Hai-hong1, YUAN Jian-feng1, YAN Hong-mei3
Author information +
文章历史 +

摘要

目的  探讨汉黄芩素(Wog)对乙型肝炎大鼠肝脏组织纤维化的影响及其调控Hippo-Yes相关蛋白(YAP)/含PDZ结合基序的转录共激活因子(TAZ)信号通路的机制。方法  大鼠随机分为正常对照(NC)组,模型(Mod)组、Wog低、中和高剂量组(Wog-L,10 mg/kg,Wog-M,20 mg/kg,Wog-H,40 mg/kg)、Wog-H+Hippo抑制剂组(40 mg/kg Wog+7 mg/kg XMU-MP-1),每组12只;除NC组,其余组均利用乙型肝炎病毒(HBV)建立大鼠模型,每周1次,连续注射3周。ELISA试剂盒检测各组大鼠血清肝功能指标:天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、谷氨酰转肽酶(GGT)、乙型肝炎E抗原(HBeAg)、乙型肝炎病毒表面抗原(HBsAg)和炎性因子转化生长因子β(TGF-β)、血小板衍生生长因子(PDGF);肝纤维化指标:Ⅳ型胶原(Col-Ⅳ)、透明质酸(HA)、Ⅲ型前胶原肽(PⅢP)和层粘连蛋白(LN);羟脯氨酸(Hyp)检测试剂盒检测Hyp水平;HE和Masson染色检测大鼠肝组织形态及纤维化;TUNEL法检测肝组织细胞凋亡;Western blotting检测肝组织α-平滑肌肌动蛋白(α-SMA)、Ⅰ型胶原蛋白(Col-Ⅰ)、Hippo-YAP/TAZ信号通路相关蛋白表达;Real-time PCR检测肝组织YAP、TAZ mRNA表达。结果 与NC组相比,Mod组大鼠肝组织中细胞肿胀、排列异常且胶原纤维增生,肝纤维化明显,血清AST、GGT、ALT、HBeAg、HBsAg、TGF-β、PDGF、Col-Ⅳ、PⅢP、LN、HA及肝组织中胶原纤维沉积比例、Hyp水平、α-SMA、Col-Ⅰ蛋白表达和细胞凋亡率等显著升高(P<0.05),YAP、TAZ蛋白和mRNA水平升高(P<0.05);与Mod组相比,Wog各剂量组大鼠的肝组织损伤减轻,血清肝功能相关指标及肝组织中胶原纤维沉积比例、Hyp水平、α-SMA、Col-Ⅰ蛋白表达和细胞凋亡率等显著降低(P<0.05),YAP、TAZ蛋白和mRNA表达水平降低(P<0.05);与Wog-H组比较,加抑制剂组肝组织纤维化损伤明显加重(P<0.05)。结论  Wog可能通过调控Hippo-YAP/TAZ信号通路活性,减轻乙型肝炎大鼠肝组织纤维化。

Abstract

Objective  To investigate the effect of wogonin (Wog) on liver fibrosis in rats with hepatitis B and the mechanism of regulating Hippo-Yes-associated protein (YAP) / transcriptional coactivator with PDZ-binding motif (TAZ) signaling pathway. Methods  Rats were randomly grouped into normal control (NC) group, model group(Mod), low-dose Wog group (Wog-L 10 mg/kg), medium-dose Wog group (Wog-M 20 mg/kg), high-dose Wog group (Wog-H 40 mg/kg), and Wog-H+Hippo inhibitor group (40 mg/kg Wog+7 mg/kg XMU-MP-1), each with 12 rats. Except for the NC group, rat model was established using hepatitis B virus (HBV) in other groups, injected once a week for three consecutive weeks. ELISA assay was used to detect serum liver function indicators, aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyl transpeptidase (GGT), hepatitis Be antigen (HBeAg), hepatitis B virus surface antigen (HBsAg), and inflammatory factors, transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and liver fibrosis indicators, type Ⅳ collagen (Col-Ⅳ), hyaluronic acid (HA), type Ⅲ procollagen peptide (PⅢP), and laminin (LN). Hydroxyproline (Hyp) detection kit for detecting Hyp levels. HE and Masson staining were used to detect the morphology and fibrosis of liver tissue. TUNEL method was used to detect cell apoptosis in liver tissue. Western blotting was used to estimate the expression of α-smooth muscle actin (α-SMA), type Ⅰ collagen (Col-Ⅰ), and proteins related to Hippo-YAP/TAZ signaling pathway. Real-time PCR was used to detect the mRNA expressions of YAP and TAZ in liver tissues. Results  Compared with the NC group, the model group showed swelling, abnormal arrangement of cells, and obvious collagen fiber proliferation in the liver tissue, the levels of serum AST, GGT, ALT, HBeAg, HBsAg, TGF-β, PDGF, Col-Ⅳ, PⅢP, LN, HA, and the proportion of collagen fiber deposition in liver tissues, as well as the levels of Hyp, α-SMA, Col-Ⅰ protein expression, and the apoptosis rate obviously increased (P<0.05), and the protein and mRNA expression levels of YAP and TAZ increased significantly(P<0.05). Compared with the model group, the liver tissue damage of rats in each dose Wog group was reduced, the levels of serum-related indicators, and the proportion of collagen fiber deposition in liver tissues, as well as the levels of Hyp, α-SMA, Col-Ⅰ protein expression, and the apoptosis rate, and the protein and mRNA expression levels of YAP and TAZ significantly reduced (P<0.05). Compared with the Wog-H group, the Wog-H+XMU-MP-1 group showed obvious liver fibrosis damage (P<0.05). Conclusion  Wog may alleviate liver fibrosis in rats with hepatitis B by regulating activity of the Hippo-YAP/TAZ pathway.

关键词

乙型肝炎 / 汉黄芩素 / Hippo-Yes相关蛋白/含PDZ结合基序的转录共激活因子信号通路 / 肝纤维化 / 免疫印迹法 / 大鼠

Key words

Hepatitis B
/ Wogonin / Hippo-Yes-associated protein/transcriptional coactivator with PDZ-binding motif signaling pathway / Liver fibrosis / Western blotting / Rat

引用本文

导出引用
邹晓婷 邓陈松 胡际涛 向海鸿 袁剑峰 严红梅. 汉黄芩素通过Hippo-Yes相关蛋白/含PDZ结合基序的转录共激活因子信号通路调控肝纤维化[J]. 解剖学报. 2026, 57(2): 185-193 https://doi.org/10.16098/j.issn.0529-1356.2026.02.006
ZOU Xiao-ting, DENG Chen-song, HU Ji-tao, XIANG Hai-hong, YUAN Jian-feng, YAN Hong-mei. Effect of wogonin on liver fibrosis by regulating the Hippo-Yes-associated protein/transcriptional coactivator with PDZ-binding motif signaling pathway[J]. Acta Anatomica Sinica. 2026, 57(2): 185-193 https://doi.org/10.16098/j.issn.0529-1356.2026.02.006
中图分类号: R361    R285.5   

参考文献

[1] Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment[J]. Am Fam Physician, 2019, 99(5):314-323.
[2] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2):e00046-19.
[3] Sinha P, Thio CL, Balagopal A. Intracellular host restriction of hepatitis B virus replication[J]. Viruses, 2024, 16(5):764.
[4] Dilcan KH, Gozdas HT. Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients[J]. Acta Gastroenterol Belg, 2024, 87(3):388-392.
[5] Wu D, Liu Z, Song Z, et al. A novel chronic hepatitis B mouse model with immune activation and liver fibrosis[J]. Microbiol Spectr, 2025, 13(9):e0251324.
[6] Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer[J].Clin Sci (Lond), 2022, 136(3):197-222.

[7] Wang L, Zhao XP, Xie JJ, et al. The roles of Hippo-YAP/TAZ and Notch signaling pathways in liver fibrosis [J]. Chemistry of Life, 2023, 43(3):402-407. (in Chinese)

王莉, 赵秀萍, 谢娇娇, 等. Hippo-YAP/TAZ与Notch信号通路在肝纤维化中的作用[J].生命的化学, 2023, 43(3):402-407.

[8] Driskill JH, Pan D. The hippo pathway in liver homeostasis and pathophysiology[J]. Annu Rev Pathol, 2021, 16:299-322.
[9] Yang MH, Ran HQ, Wang HB, et al. Effects of Wogonin on liver fibrosis in cirrhotic rats by regulating the Hippo/YAP signaling pathway[J]. Journal of Hunan University of Chinese Medicine, 2024, 44(7):1160-1166. (in Chinese)
杨茂辉, 冉恒泉, 王何斌, 等. 汉黄芩素调节Hippo/YAP信号通路对肝硬化大鼠肝纤维化的影响[J]. 湖南中医药大学学报, 2024, 44(7):1160-1166.
[10] Qu YN, Xin XL, Zhou HJ. Wogonin reduces the degree of fibrosis in cirrhotic rats by regulating Hedgehog-YAP signal pathway[J]. Chinese Journal of Anatomy, 2024, 47(1):35-39, 80. (in Chinese)
瞿旖妮, 辛晓丽, 周慧君. 汉黄芩素通过调节Hedgehog-YAP信号通路减轻肝硬化大鼠的肝纤维化[J]. 解剖学杂志, 2024, 47(1):35-39, 80.
[11] Wang Y, Wang LZh, Wang YD, et al. Influence of asiaticoside on liver fibrosis in hepatitis B model rats by inhibiting TGF-β1/Smad signaling pathway[J]. Infectious Disease Information, 2022, 35(6):496-501. (in Chinese)
汪燕, 王立志, 王运东, 等. 积雪草苷抑制TGF-β1/Smad信号通路对乙型肝炎模型大鼠肝纤维化的影响[J]. 传染病信息, 2022, 35(6):496-501.
[12] Zhou X, Wang H, Li D, et al. MST1/2 inhibitor XMU-MP-1 alleviates the injury induced by ionizing radiation in haematopoietic and intestinal system[J]. J Cell Mol Med, 2022, 26(5):1621-1628.
[13] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3):230-238.
[14] Luo RL, Li SQ, Feng JY, et al. Effects and mechanisms of exogenous thyroid hormone t3 on liver oxidative stress in mice with alcoholic liver fibrosis[J]. Acta Anatomica Sinica, 2024, 55(6):753-760.  (in Chinese)
罗仁利, 李三强, 冯家阳, 等. 外源性甲状腺激素T3对酒精性肝纤维化小鼠肝脏氧化应激的影响及其机制[J]. 解剖学报, 2024, 55(6):753-760.
[15] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65:37-55.
[16] Yu X, Gao Y, Zhang X, et al. Hepatitis B: model systems and therapeutic approaches[J]. J Immunol Res, 2024, 2024:4722047.
[17] Spyrou E, Smith CI, Ghany MG. Hepatitis B: current status of therapy and future therapies[J].Gastroenterol Clin North Am, 2020, 49(2):215-238.
[18] Sharifi-Rad J, Herrera-Bravo J, Salazar LA, et al. The therapeutic potential of wogonin observed in preclinical studies[J]. Evid Based Complement Alternat Med, 2021, 2021:9935451.
[19] He X, Wang J, Sun L, et al. Wogonin attenuates inflammation and oxidative stress in lipopolysaccharide-induced mastitis by inhibiting Akt/NF-κB pathway and activating the Nrf2/HO-1 signaling[J]. Cell Stress Chaperones, 2023, 28(6):989-999.
[20] Yamada Y, Saito H, Araki M, et al. Wogonin, a compound in scutellaria baicalensis, activates ATF4-FGF21 signaling in mouse hepatocyte AML12 cells[J]. Nutrients, 2022, 14(19):3920.
[21] Naderi M, Salavatiha Z, Gogoi U, et al. An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action[J]. Front Cell Infect Microbiol, 2024, 14:1356003.
[22] Liu Y, Wang X, Yang Y. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2020, 26(4):742-750.
[23] Moon H, Cho K, Shin S, et al. High risk of hepatocellular carcinoma development in fibrotic liver: role of the Hippo-YAP/TAZ signaling pathway[J]. Int J Mol Sci, 2019, 20(3):581.
[24] Nishina H. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis[J]. Cancer Sci, 2022, 113(6):1900-1908.

基金

武汉市卫生健康委员会项目(WX20D17)

PDF(14053 KB)

Accesses

Citation

Detail

段落导航
相关文章

/